Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 189

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 189
---
 to the acquisition of Amunix Pharmaceuticals, Inc (€ 852 million), partly offset by the proceeds of €150 million from the sale of a 12% equity interest in EUROAPI to EPIC Bpifrance. Acquisitions of property, plant and equipment and intangible assets amounted to € 2,906 million in 2023 versus € 2,103 million in 2022 . There were € 1,619 million of acquisitions of property, plant and equipment (versus € 1,529 million in 2022 ), most of which related to industrial facilities. Acquisitions of intangible assets (€ 1,287 million in 2023 versus € 574 million in 2022 ) mainly comprised contractual payments for intangible rights under license and collaboration agreements. After-tax proceeds from disposals (€ 807 million in 2023 versus € 1,340 million in 2022 ) exclude proceeds from divestments of investments in consolidated undertakings and investments accounted for using the equity method, and mainly comprised divestments of assets and activities related to the streamlining of the portfolio, and disposals of equity and debt instruments. Net cash provided by/used in continuing financing activities represented a net cash outflow € 8,048 million in 2023 versus a net cash outflow of € 5,807 million in 2022 . The 2023 figure includes the redemption of bond issues totalling € 3,664 million. Other movements included (i) the dividend payout to our shareholders of € 4,454 million (versus € 4,168 million in 2022 ); and (ii) the effect of changes in our share capital (repurchases of our own shares, net of capital increases), representing a net cash outflow of € 398 million in 2023 versus a net cash outflow of € 309 million in 2022 . The net change in cash and cash equivalents of continuing operations in 2023 was a decrease of € 3,727 million, versus an increase of € 1,714 million in 2022 . Net cash flows for the discontinued Opella business represented net cash outflows of € 267 million in 2023 versus a net cash inflows € 916 million in 2022 . The net change in cash and cash equivalents during 2023 was a reduction of € 4,026 million; this compares with an increase of € 2,638 million in 2022 . “Free cash